news
Pharma M&A activity up 17 percent year-on-year in H1 of 2020
A new report has highlighted that despite the pandemic, pharma M&A activity rose but deal value fell in the first half of 2020.
List view / Grid view
Mergers & Acquisitions
![Phone screen displaying PerkinElmer logo next to a laptop keyboard [Credit: rafapress / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/PerkinElmer-3-300x278.jpg)
![Phone screen displaying PerkinElmer logo next to a laptop keyboard [Credit: rafapress / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/PerkinElmer-3-scaled-e1604320818816.jpg)
news
PerkinElmer to acquire Horizon Discovery for $383 Million
PerkinElmer will expand its automated life sciences discovery and applied genomics solutions with the acquisition.
article
How can virtual pharma companies de-risk new product launches?
Christoph Krähenbühl outlines five considerations for virtual pharmaceutical companies when launching a new drug product.
news
Majority of CMO-acquired dose manufacturing facilities in Europe, report says
A new report has found that three quarters of dose manufacturing facilities acquired by dedicated CMOs in 2019 were in Europe.
news
Gilead Sciences to acquire Immunomedics for $21 billion
Gilead is set to acquire Immunomedics for approximately $21 billion, with the transaction anticipated to close in the fourth quarter of 2020.
news
Nestlé Health Science to acquire Aimmune Therapeutics for $2.6 billion
Nestlé Health Science will acquire Aimmune Therapeutics for a total value of $2.6 billion, extending the former's food allergy portfolio.
news
Sanofi to acquire Principa Biopharma for $3.68 billion
Sanofi is set to acquire Principia Biopharma Inc. for a total aggregate equity value of $3.68 billion, at $100 per share.
news
Bayer to acquire KaNDy Therapeutics with $425 million upfront payment
Bayer will acquire KaNDy Therapeutics Ltd for an upfront cost of $425 million to expand its drug development pipeline in women’s healthcare.
news
Licensing agreement deals decline in rare diseases space, says report
New research has shown that complex collaborations and partnerships are increasing, while licensing agreements are decreasing in the rare disease space.
article
Outsourcing update: the latest developments in pharma
European Pharmaceutical Review explores some of the latest developments in outsourcing, including clinical development and production agreements; acquisitions and collaborations; and expansions.
article
Life sciences M&A activity during the global pandemic
COVID-19 has severely disrupted the lives of many people around the world. In this article, corporate partner Theo Godfrey and competition partner Russell Hoare from the life sciences team at law firm CMS Cameron McKenna Nabarro Olswang LLP consider some issues related to COVID-19 that have impacted life sciences merger…
news
FTC accepts proposal for AbbVie to acquire Allergan for $63 billion
AbbVie and Allergan have announced the Federal Trade Commission has accepted AbbVie's pending acquisition of Allergan for $63 billion.
news
Sartorius closes acquisition of selected assets of Danaher Life Sciences
Sartorius has announced the completed acquisition of some life science businesses of Danaher for a total of $825 million.
news
Evox and Takeda sign deal to collaborate on rare disease treatments
In an $882 million deal, Evox and Takeda will partner to develop and manufacture treatments and drug delivery systems for rare diseases.
news
Mylan and Upjohn transaction closure delayed by COVID-19
Mylan and Upjohn (a Pfizer company) revealed they have delayed the transaction due to meeting restrictions and concerns over staff health and safety during the COVID-19 pandemic.
